{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:53:15Z","timestamp":1791211995698,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T16:24:03Z","timestamp":1713457443000},"page":"629-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2024.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.04.007_bib0002","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.04.007_bib0003","doi-asserted-by":"crossref","first-page":"e00233","DOI":"10.1002\/rcr2.233","article-title":"Lenalidomide-induced eosinophilic pneumonia","volume":"5","author":"Toma","year":"2017","journal-title":"Respirol Case Rep"},{"issue":"2","key":"10.1016\/j.clml.2024.04.007_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jcpt.12611","article-title":"Eosinophilia secondary to lenalidomide therapy","volume":"43","author":"Escudero-Vilaplana","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.clml.2024.04.007_bib0005","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1684\/ejd.2012.1853","article-title":"Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide","volume":"22","author":"Foti","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.clml.2024.04.007_bib0006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/1078155211408374","article-title":"Reversible pulmonary toxicity due to lenalidomide","volume":"18","author":"Coates","year":"2012","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.clml.2024.04.007_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000305213","article-title":"A case of lenalidomide-induced hypersensitivity pneumonitis","volume":"33","author":"Lerch","year":"2010","journal-title":"Onkologie"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.04.007_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12288-014-0355-7","article-title":"Patient with refractory multiple myeloma developing eosinophilia after lenalidomide treatment and lung cancer 9 months later: case report and review of the literature","volume":"30","author":"Sekiguchi","year":"2014","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:49:41Z","timestamp":1724460581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001691"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}